NC
NVCR icon

NinePointTwo Capital’s NovoCure NVCR Stock Holding History

NinePointTwo Capital’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$330K Buy
+22,164
New +$297K 0.13% 97

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

NinePointTwo Capital's NVCR Position: Q4 2023 in Review

NinePointTwo Capital opened a new position in NovoCure (NVCR) in Q4 2023: 22,164 shares worth $330K. The stake represents 0.13% of the portfolio and ranks #97 among its holdings.

219 funds tracked by Wall St. Rank hold NVCR as of Q4 2023.

  • NinePointTwo Capital held 22,164 shares of NovoCure worth $330K as of Q4 2023.
  • NovoCure was a new NinePointTwo Capital position in Q4 2023.
  • NovoCure made up 0.13% of NinePointTwo Capital's portfolio in Q4 2023, its #97 holding.
  • 219 funds tracked by Wall St. Rank held NovoCure as of Q4 2023.

Based on NinePointTwo Capital's 13F filing for Q4 2023, filed 14 Feb 2024.